Kyowa Hakko Kogyo Co., a Japanese biotechnology and pharmaceutical company, announced Monday the creation of a new unit in the United States to develop and market monoclonal antibodies and other biological technologies and businesses.

Kyowa Hakko, the nation’s largest fermented-chemical company, said BioWa Inc., a wholly owned subsidiary in Princeton, N.J., of Kyowa America Inc., is intended to tap the rapidly growing antibody therapeutic industry with antibody medicines.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.